ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the subsidy status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the subsidy recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 03 Aug 2021
Last Updated on 31 Aug 2022
A- A+
Ixekizumab and secukinumab for treating active ankylosing spondylitis Guidance is outdated and has been withdrawn on 31 August 2022. The Plain English Summary (PES) has been updated on 31 August 2022.
Ixekizumab and secukinumab for treating active ankylosing spondylitis PES (Updated-31 Aug 22) Ixekizumab and secukinumab for treating active ankylosing spondylitis (Withdrawn 31 Aug 22)